Sandra Visser, PhD, GlaxoSmithKline
personal info
Sandra Visser received her PhD in quantitative pharmacology from Leiden University in The Netherlands. She is passionate about leading teams in the application of clinical pharmacology and quantitative methodologies to inform drug development strategies in drug research and development to drive project, portfolio, and patient value and to improve R&D decision making. During her tenure at GSK she built an effective clinical pharmacology M&S team to support a significant, diverse and maturing Oncology portfolio and has managed the global development governance board across all therapeutic areas. Also, she is the President-Elect for the American Society of Clinical Pharmacology and Therapeutics after serving ASCPT in multiple leadership roles. Throughout her career, she has brought the vision of model-informed drug discovery and development (MID3) to life through workshops and publications.